Given Imaging to Host Fourth Quarter and Full Year 2012

Given Imaging to Host Fourth Quarter and Full Year 2012 Financial
Results Conference Call on February 13, 2013 
YOQNEAM, ISRAEL -- (Marketwire) -- 01/23/13 --  Given Imaging
(NASDAQ: GIVN) today announced that the company will host a
conference call on Wednesday, February 13, 2013 at 9:00am ET, 4:00pm
Israel time to discuss fourth quarter 2012 financial results. The
company plans to release results following the close of U.S.
financial markets on Tuesday, February 12, 2013. 
To participate in the teleconference, please dial the following
numbers fifteen minutes before the call is scheduled to begin: U.S.
and Canada, 1-888-438-5448; Israel, 1-80-924-5906. Callers in other
countries should dial 719-457-2645. The call will also be webcast
live at www.givenimaging.com.  
A replay of the call will be available for two weeks on the company's
website, or until February 27, 2013, by dialing 888-203-1112. Callers
in Israel should dial 1-80-924-6038. Callers outside of the U.S. and
Israel should dial 719-457-0820. The replay participant code is
9489476. 
About Given Imaging Ltd.
 Since pioneering the field of capsule
endoscopy in 2001, Given Imaging has become a world leader in GI
medical devices, offering health care providers a range of innovative
options for visualizing, diagnosing and monitoring the digestive
system. The company offers a broad product portfolio including
PillCam(R) capsule endoscope for the small bowel, esophagus and
colon. The company also offers industry-leading GI functional
diagnostic solutions including ManoScan(TM) high-resolution
manometry, Bravo(R) capsule-based pH monitoring, Digitrapper(R) pH-Z
impedance, and the SmartPill(R) GI monitoring systems. Given Imaging
is committed to delivering breakthrough innovations to the GI
community and supporting its ongoing clinical needs. Given Imaging's
headquarters are located in Yoqneam, Israel, with operating
subsidiaries in the United States, Germany, France, Japan, Australia,
Vietnam, Hong Kong and Brazil. For more information, please visit
www.givenimaging.com. 
Forward-Looking Statements 
 This press release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements inc
lude, but are not limited
to, projections about our business and our future revenues, expenses
and profitability. Forward-looking statements may be, but are not
necessarily, identified by the use of forward-looking terminology
such as "may," "anticipates," "estimates," "expects," "intends,"
"plans," "believes," and words and terms of similar substance.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual events,
results, performance, circumstances or achievements of the Company to
be materially different from any future events, results, performance,
circumstances or achievements expressed or implied by such
forward-looking statements. Such forward-looking statements include
statements relating to the Company exploring strategic alternatives
and considering possible strategic transactions involving the
Company. Factors that could cause actual events, results,
performance, circumstances or achievements to differ from such
forward-looking statements include, but are not limited to, the
ability of the Company to reach agreement on any strategic
alternative and/or to complete any such alternative, as well as the
following: (1) our ability to develop and bring to market new
products, (2) our ability to successfully complete any necessary or
required clinical studies with our products, (3) our ability to
receive regulatory clearance or approval to market our products or
changes in regulatory environment, (4) our success in implementing
our sales, marketing and manufacturing plans, (5) the level of
adoption of our products by medical practitioners, (6) the emergence
of other products that may make our products obsolete, (7) lack of an
appropriate bowel preparation materials to be used with our PillCam
COLON capsule, (8) protection and validity of patents and other
intellectual property rights, (9) the impact of currency exchange
rates, (10) the effect of competition by other companies, (11) the
outcome of significant litigation, (12) our ability to obtain
reimbursement for our product from government and commercial payors,
(13) quarterly variations in operating results, (14) the possibility
of armed conflict or civil or military unrest in Israel, (15) the
impact of global economic conditions, (16) our ability to
successfully integrate acquired businesses, (17) changes and reforms
in applicable healthcare laws and regulations, (18) quality issues
and adverse events related to our products, such as capsule
retention, aspiration and failure to attach or detach, bleeding or
perforation that could require us to recall products and impact our
sales and net income, and (19) other risks and factors disclosed in
our filings with the U.S. Securities and Exchange Commission,
including, but not limited to, risks and factors identified under
such headings as "Risk Factors," "Cautionary Language Regarding
Forward-Looking Statements" and "Operating Results and Financial
Review and Prospects" in the Company's Annual Report on Form 20-F for
the year ended December 31, 2011. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only
as of the date of this press release. Except to the extent expressly
required under applicable law, the Company undertakes no obligation
to release publicly any revisions to any forward-looking statements,
to report events or to report the occurrence of unanticipated events. 
For further information contact:
Fern Lazar/David Carey
Lazar Partners Ltd.
212 867 1768
flazar@lazarpartners.com
dcarey@lazarpartners.com 
Israel Investor Contact: 
Nava Ladin 
Gelbart Kahana Investor Relations 
+972-3-6074717 
nava@gk-biz.com 
 
 
Press spacebar to pause and continue. Press esc to stop.